This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Myasthenia Gravis  • Neuromuscular diseases  • Public Health  • Immunization  • Hematology/ Hematologic Malignancies  • Hematology, Other  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Part 2. Treatment of Neuromuscular Disorders

Helmar C. Lehmann, MD; Hans-Peter Hartung, MD; Gerd R. Hetzel, MD; Olaf Stüve, MD; Bernd C. Kieseier, MD

Arch Neurol. 2006;63:1066-1071.

Plasma exchange is a well-established therapeutic procedure commonly used in many neurological disorders of autoimmune etiology. In this second part of our review, we assess the role of plasma exchange in the treatment of neuromuscular disorders. In Guillain-Barré syndrome and other immune-mediated neuropathic disorders, randomized controlled trials have demonstrated the therapeutic efficacy of plasma exchange. Myasthenia gravis and Lambert-Eaton syndrome represent neuromuscular disorders where plasmapheresis might be of potential efficacy.

Author Affiliations: Departments of Neurology (Drs Lehmann, Hartung, and Kieseier) and Nephrology (Dr Hetzel), Heinrich Heine University of Düsseldorf, Düsseldorf, Germany; and Department of Neurology, The University of Texas Southwestern Medical Center at Dallas (Dr Stüve).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction
Plomp and Willison
J. Physiol. 2009;587:3979-3999.
ABSTRACT | FULL TEXT  

Review: Pathogenesis and treatment of immune-mediated neuropathies
Lehmann et al.
Therapeutic Advances in Neurological Disorders 2009;2:261-281.
ABSTRACT  

Review: Natalizumab in the treatment of multiple sclerosis
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT  

Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies
Lehmann and Hartung
Brain 2008;131:1168-1170.
FULL TEXT  

Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions
Stuve et al.
Arch Neurol 2007;64:169-176.
ABSTRACT | FULL TEXT